• Dayana Bravo, José Blanquer, Mar Tormo, Gerardo Aguilar, Rafael Borrás, Carlos Solano, María A Clari, Elisa Costa, Beatriz Muñoz-Cobo, Mónica Argüeso, José Roberto Pineda, and David Navarro.
• Microbiology Service, Hospital Clínico Universitario, Av. Blasco Ibáñez 17, 46010 Valencia, Spain. david.navarro@uv.es
• Int. J. Infect. Dis. 2011 May 1;15(5):e326-31.

ObjectivesThe objectives of this study were to compare the performance of the LightCycler SeptiFast Test MGRADE and conventional blood culture in the etiological diagnosis of febrile episodes occurring in neutropenic and critically ill patients (in the intensive care unit; ICU), and to assess the potential clinical value of the SeptiFast test in patient management.MethodsA total of 86 febrile episodes occurring in 33 neutropenic patients and 53 ICU patients were analyzed. Blood samples for blood culture and SeptiFast testing were obtained at the onset of fever, before the implementation of empirical antimicrobial therapy.ResultsThe overall microorganism-to-isolate agreement between the SeptiFast test and blood culture was 69% (κ=0.37) in neutropenic patients and 75% (κ=0.56) in ICU patients. The sensitivity of the SeptiFast assay for clinically relevant episodes of bacteremia and fungemia was 62% in neutropenic patients and 70% in ICU patients. Based on SeptiFast results, empirical treatments were deemed adequate in all but one of the febrile episodes. Nevertheless, early antibiotic treatment readjustment was judged feasible in most of clinically significant episodes overall.ConclusionsThe SeptiFast assay is a valuable ancillary method for the diagnosis of bloodstream infections in neutropenic and ICU patients. In these clinical settings, results of the SeptiFast assay may lead to a more targeted antibiotic therapy early after the onset of fever.Copyright © 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

37 keywords...

hide…